RxDoctor Payments Data

Erin Desrosiers, PA

Physician Assistant · Williamsburg, VANPI 1659564557

Payments from drug & device makers

$4,180in general payments, 2019–2025

Across 152 payments — averaging $27.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$836
  • AbbVie$597
  • Sumitomo Pharma America, Inc.$409
  • Accord Healthcare, Inc.$264
  • Bayer$188
  • Johnson & Johnson$144
  • plus $2K from 28 others

What the payments were for

  • Travel & lodging$54013%
  • Food & beverage$3,64187%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,180 in reported general payments places this provider in the 90th percentile of 3,376 physician assistant providers in Virginia.

See all physician assistant providers in Virginia

Medicare billing

Part B allowed, 2024
$119,894
Medicare patients
623
Services billed
2,522

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron35$38,206
MyrbetriqMirabegron38$33,071
Trospium Chloride29$2,081
Tamsulosin Hcl147$1,997
Testosterone Cypionate15$691
NitrofurantoinNitrofurantoin Macrocrystal12$530
Cephalexin62$416
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst26$377
Alfuzosin Hcl ErAlfuzosin Hcl24$285
Finasteride19$238
Ciprofloxacin Hcl53$227
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim37$218
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav24$153
Cefdinir13$112

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$409$38,20635 claims
Astellas Pharma US IncMyrbetriq$95$33,07138 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,376 physician assistant providers in Virginia.

Other physician assistant in Williamsburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →